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Ribosome-associated mRNA quality control mechanisms ensure fidelity of protein 29 
translation1,2. Although extensively studied in yeast, little is known about their role in 30 
mammalian tissues, despite emerging evidence that stem cell fate is controlled by 31 
translational mechanisms3,4. One evolutionarily conserved component of the quality control 32 
machinery, Dom34/Pelota (Pelo), rescues stalled ribosomes5. Here we show that Pelo is 33 
required for mammalian epidermal homeostasis. Conditional deletion of Pelo in those 34 
murine epidermal stem cells that express Lrig1 results in hyperproliferation and abnormal 35 
differentiation. In contrast, deletion in Lgr5+ stem cells has no effect and deletion in Lgr6+ 36 
stem cells has only a mild phenotype. Loss of Pelo results in accumulation of short 37 
ribosome footprints and global upregulation of translation rather than affecting expression 38 
of specific genes. Translational inhibition by rapamycin-mediated down regulation of 39 
mTOR rescues the epidermal phenotype. Our study reveals a novel role for the ribosome-40 
rescue machinery in mammalian tissue homeostasis and an unanticipated specificity in its 41 
impact on different stem cell populations.  42 
Pelo is expressed in mouse skin dermis and epidermis6 (Extended Data Fig. 1a). Dermal-specific 43 
deletion (PeloderKO) resulted in mice that were smaller than littermate controls but had a normal 44 
lifespan and no dermal abnormalities (Fig. 1a-f). Although Dom34 forms a functional complex 45 
with Hbs1 in yeast7 and the mammalian homolog Hbs1l is expressed in mouse skin6 (Extended 46 
Data Fig. 1b), the Hbs1l knockout (from exon 5; Extended Data Fig. 1c) had no epidermal 47 
defects (Extended Data Fig. 1d-f) and only small changes in dermal collagen deposition, 48 
thickness and cell density (Extended Data Fig. 1f-m). Another Pelo partner, Gtpbp28, does not 49 
have a reported skin phenotype.  50 
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Selective embryonic deletion of Pelo in Krt14 expressing epidermal cells, comprising the known 51 
stem cell subpopulations9, via Krt14Cre (PeloepiKO; Fig. 1g) phenocopied deletion via the 52 
ubiquitous Rosa26 locus10. Mice were born with scaly skin and an epidermal barrier defect 53 
(increased trans epidermal water loss; TEWL). They exhibited hair and weight loss, failing to 54 
thrive beyond 5 months (Fig. 1h-k). Epidermal thickening resulted from increased proliferation 55 
(Fig. 1l-s) and abnormal accumulation of differentiated cells (Fig. 1n-t). Wound closure was 56 
delayed (Fig. 1u), correlating with reduced proliferation, differentiation and migration (Extended 57 
Data Fig. 2a-i). Hyperproliferation in unwounded skin combined with delayed wound healing 58 
and abnormal differentiation has been observed in other mouse models11. There was also striking 59 
degeneration of the sebaceous glands and hair follicles, correlating with loss of the hair follicle 60 
bulge stem cell markers Krt15 and CD34 and the junctional zone stem cell marker Lrig1 61 
(Extended Data Fig. 3a-c).  62 
 63 
To determine whether the Pelo epidermal phenotype could be induced postnatally, we applied 4-64 
OHT to adult Pelofl/fl; Krt14CreERT (Extended Data Fig. 4a, b). Mice developed skin lesions, 65 
increased TEWL and delayed wound closure (Extended Data Fig. 4c-e). Degeneration of hair 66 
follicles and sebaceous glands correlated with keratinized cyst formation (Extended Data Fig. 4f, 67 
g). Sebocyte differentiation was disturbed, accompanied by expansion of Lrig1 labelling into the 68 
upper sebaceous gland (Extended Data Fig. 4h, i).  69 
 70 
PELO knockdown in cultured human epidermal keratinocytes led to an increase in stem cell 71 
colonies (Extended Data Fig. 5a-g). Immunostaining of epidermis reconstituted on decellularised 72 
dermis revealed increased proliferation of basal layer cells and increased differentiated layers 73 
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(Extended Data Fig. 5h-l). Therefore the mouse epidermal Pelo phenotype was recapitulated in 74 
human cells. 75 
 76 
To determine if there is a differential requirement for Pelo in different epidermal subpopulations, 77 
we conditionally deleted Pelo in Lgr5+, Lgr6+ and Lrig1+ stem cells (Fig. 2a-c). Pelo deletion in 78 
Lrig1+ cells recapitulated the effects of deleting Pelo in Krt14+ cells, whereas when Pelo was 79 
deleted in Lgr5+ and Lgr6+ cells differentiation was normal (Fig. 2d) with only a small increase 80 
in Ki67+ cells (Extended Data Fig. 5m, Fig. 2f). Pelo deletion in Lrig1+ cells increased cell 81 
proliferation in the upper hair follicle, with marked changes in follicles and sebaceous glands 82 
(Fig. 2e, Extended Data Fig. 6a, b). A significant increase in proliferation and TEWL occurred in 83 
the interfollicular epidermis (IFE) of Pelofl/fl; Lrig1CreERT2 mice compared to Pelofl/fl; Lgr5CreERT2 84 
and Pelofl/fl; Lgr6CreERT2 mice (Extended Data Fig.5m, Fig. 2f, h). There was a small increase in 85 
epidermal thickness in Pelofl/fl; Lgr6CreERT2 mice but TEWL was unaffected (Fig. 2g, h).  86 
 87 
We next generated Pelofl/fl; Lrig1CreERT2; Rosa26tdTom, Pelofl/fl; Lgr5CreERT2; Rosa26tdTom, and 88 
Pelofl/fl; Lgr6CreERT2; Rosa26tdTom mice, and treated with 4-OHT. Pelo deletion did not change the 89 
contribution of Lgr5 or Lgr6 progeny to the epidermis (Extended Data Fig. 6c, d). In contrast, on 90 
Pelo deletion Lrig1 lineage cells expanded downwards into the hair follicles and fully colonized 91 
the IFE (Extended Data Fig. 6c, d). In the presence or absence of Pelo, the Lrig1 lineage 92 
accounted for most Ki67+ epidermal cells; they also accounted for the increase in proliferative 93 
cells on Pelo deletion (Extended Data Fig. 6e, f).  94 
 95 
  5
Yeast cells lacking Dom34 (the homolog of Pelo) are enriched in short 16-18 nucleotide 96 
ribosome-protected fragments (RPFs) resulting from translation to the 3´end of truncated 97 
mRNAs5. Dom34/Rli1 mutant yeast accumulate full length 28-32 nucleotide RPFs in 3´ UTRs, 98 
consistent with the role of Dom34 and Rli1 in ribosome rescue and recycling on intact mRNAs, 99 
respectively12. In anucleate hematopoietic cells PELO and ABCE1 (Rli1) rescue non-translating 100 
3´UTR ribosomes13 and impact mRNA stability14. When we performed ribosomal profiling on 101 
keratinocytes from adult PeloepiKO mice by deep sequencing RPFs15, RPFs mapped primarily to 102 
the coding sequence (CDS) (Fig. 3a; Extended Data Fig. 7a, b), consistent with studies12 showing 103 
that loss of PELO alone does not substantially increase 3´ UTR ribosomes. CDS RPFs were 104 
primarily 28-34nts, the expected fragment size protected by mammalian ribosomes16, and 105 
displayed the three-nucleotide periodicity reflecting codon-by-codon movement of elongating 106 
ribosomes (Fig. 3b, gray bars). 107 
  108 
PeloepiKO profiles were enriched in 20-21 nucleotide RPFs (~4-5% of total RPFs compared to 109 
<1% in control cells) (Fig. 3a-c). Like the dominant population of 28-34nt RPFs, these footprints 110 
were primarily found in the CDS and showed a strong reading frame signal, indicating they too 111 
reflect the presence of elongating ribosomes, yet are shortened on their 3´ end after nuclease 112 
digestion (Fig. 3d, right). The density of short RPFs was evenly distributed and did not increase 113 
in frequency near the downstream 3´ portion of transcripts (Fig. 3a), as would be anticipated if 114 
they resulted from ribosomes encountering a directional RNA decay process17,18. Consistent with 115 
this, enrichment for 20-21 nt footprints was not linked to reduced transcript abundance in 116 
PeloepiKO cells (Fig. 3e; Supplementary Table 1). While Pelo is implicated in decay of the 117 
unusual histone mRNAs that lack polyA tails19, the short footprints did not demonstrate patterns 118 
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to indicate they result from ribosomes occupying transcripts that are being degraded. The 21mer 119 
RPFs seen in PeloepiKO cells could be the equivalent of the 16mer species in yeast5 and reflect the 120 
increased size of the mammalian ribosome20. However, we suggest they are equivalent to the 121 
21nt fragments observed21 in anisomycin-treated yeast cells and reflect dependence on Pelo-122 
associated quality control mechanisms in response to tRNA starvation in rapidly dividing cells. 123 
 124 
Epidermal Pelo loss led to significant changes in global translational efficiency (TE)15 (Fig. 3f, 125 
g; p < 0.01). TE values for keratins and ribosomal proteins were notably increased (Fig. 3f, g). 126 
There was significant enrichment for genes involved in RNA metabolism, protein synthesis, 127 
extracellular matrix and chromatin regulation (Fig. 3h; Extended Data Fig. 7c to e; 128 
Supplementary Table 2; Supplementary Table 3). There was also differential expression of 129 
canonical translational pathways, including upregulation of the mTOR (mechanistic target of 130 
rapamycin) pathway (Fig. 3h; Extended Data Fig. 8a, b). Since mTOR signaling leads to 131 
increased global translation22 (Extended Data Fig. 8c), we compared the Gtpbp2/tRNA mutant8 132 
and PeloepiKO gene expression datasets. We found significant overlap in translational signaling 133 
pathways (Extended Data Fig. 8d), suggesting that ribosome stalling is sensed by mTOR. 134 
 135 
The polysome-to-monosome ratio was increased in PeloepiKO cells (Fig. 3i), suggesting an overall 136 
increase in translation or accumulation of inactive stalled ribosomes. Krt86 transcripts were 137 
enriched in the heavy polysome fractions (Fig. 3j), consistent with the increases in TE values, 138 
suggesting increased overall translation. This was confirmed by quantifying global protein 139 
synthesis by O-propargyl-puromycin (OP-P) incorporation into newly synthesized polypeptide 140 
chains3,4. OP-P incorporation was increased in PeloepiKO IFE and hair follicles compared to 141 
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controls. Labelling was higher in the IFE suprabasal than basal layer, consistent with increased 142 
total protein synthesis during differentiation (Fig. 4a-d)23. The increase in OP-P labelling in total 143 
Pelo null keratinocytes (Fig. 4e) and stem cells (Integrin α6-high cells; Itga6high) was confirmed 144 
by flow cytometry (Extended Data Fig. 9a, Fig. 4f-j). Confocal microscopy revealed a striking 145 
increase in the size of PeloepiKO basal cells (Extended Data Fig. 9b-d), consistent with increased 146 
protein synthesis and a higher proportion of G2/M and S phase cells (Extended Data Fig. 9e).   147 
 148 
In control mice, Lrig1+ cells exhibited slightly higher protein synthesis than Lgr5 and Lgr6+ 149 
cells (Fig. 4k, l). When Pelo was deleted, protein synthesis in Lrig1+ cells was increased further 150 
relative to Lgr5 and Lgr6+ cells (Fig. 4k, l). RNA-seq (Extended Data Fig. 10a) revealed that 151 
regardless of whether or not Pelo was expressed, Lgr5+ cells clustered separately from Lrig1+ 152 
and Lgr6+ cells, while the gene expression profiles of individual populations did not cluster 153 
based on Pelo expression (Extended Data Fig. 10b-j, Supplementary Tables 4, 5). Therefore the 154 
Pelo epidermal phenotype primarily reflects increased translation, rather than expression of 155 
specific genes. 156 
  157 
To downregulate mTOR122, we applied rapamycin to adult PeloepiKO skin (Extended Data Fig. 9f, 158 
g). There was a significant reduction in Ki67+ cells compared to controls (Extended Data Fig. 159 
9h-j). Phosphorylated ribosomal protein S6K (pS6K), a key substrate of mTOR22, was increased 160 
in PeloepiKO skin, and reduced by rapamycin (Extended Data Fig. 9k). However, rapamycin did 161 
not prevent disruption of hair follicle and sebaceous gland architecture (Extended Data Fig. 9h). 162 
 163 
  8
Simultaneous rapamycin treatment and Pelo deletion largely prevented Pelo-mediated disruption 164 
of epidermal homeostasis (Fig. 4m, n). TEWL, epidermal thickening and proliferation were 165 
substantially reduced (Fig. 4o-u; Extended Data Fig. 9l); pS6K labeling was reduced (Fig. 4v) 166 
and phosphorylation of another mTOR substrate, 4EBP1, was decreased (Extended Data Fig. 167 
9m). Therefore the epidermal Pelo deletion phenotype is largely attributable to increased protein 168 
translation. 169 
 170 
Our results indicate that translational control is critical for tissue homeostasis3,4,13 and establish a 171 
link between Pelo inactivation and translational activation via mTOR. mTOR is known to 172 
regulate cell growth and proliferation22,24 and is activated upon ribosome-stalling by Fragile X 173 
Mental Retardation Protein25,26. Impaired ribosomal biogenesis also activates mTOR1 signaling 174 
and stimulates translation initiation and elongation factors27. mTOR signaling may be activated 175 
to enhance the efficiency of the translational machinery in order to compensate for impaired or 176 
reduced availability of ribosomes8,28.  177 
 178 
The increased size of Pelo-null epidermal cells as a result of increased protein synthesis23,30 may 179 
stimulate differentiation through decreased basement membrane engagement29 and thus 180 
indirectly promote proliferation. Factors that may account for the selective sensitivity of Lrig1+ 181 
cells to Pelo deletion include their proliferative state, abundance and location relative to Lgr5+ 182 
and Lgr6+ cells, together with their known ability to repopulate different epidermal 183 
compartments31.  184 
 185 
 186 
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Fig. 1. Differential effects of Pelo deletion PeloderKO (a-f) and PeloepiKO (g-u) mice. (h) Arrows: 214 
skin abnormalities. (c, d, l, m) H&E staining of back (c, d) and tail (l, m) skin. Dermal cellularity 215 
(d) and epidermal thickness (m) were measured. n=12 sections analyzed over 3 mice per group. 216 
(e, f, n, p-r) Immunolabelling of sections (e, f, n, p) and wholemounts (q, r). Asterisks: non-217 
specific; arrow: suprabasal labelling; dashed lines: epidermal-dermal boundary. (m, n) 218 
***p<0.001, n=3 mice. (i) Kaplan-Meier curves (n=29 mice). (j) Body weight: ***p<0.0003; 219 
n=5 per group. (k) TEWL. p<0.05; n=3. (s) Quantification of proliferation. **p=0.0086; 220 
***p=0.0003 for Ki67; 0.0006 for EdU; n=3. (t) Cumulative mean values of gene expression 221 
from ribosome profiling. (u) Wound closure. *p=0.0500; n=3. Representative images in 1c, e-f, 222 
l, p-r from 3 independent experiments. Ctrl: littermate controls. Scale bars 100 μm. 223 
 224 
Fig. 2. Lrig1+ stem cells account for Pelo mutant epidermal phenotype (a-c) Schematics of 225 
Lrig1, Lgr5 and Lgr6 expression (a), breeding (b) and 4-OHT treatment (c). (d, e) 226 
Immunostaining of dorsal skin IFE sections (d) and tail wholemounts (e) with antibodies to the 227 
markers shown. (e) Asterisk: altered SG; arrow: altered JZ. (g-i) Quantification of proliferation 228 
(f), epidermal thickness (g) and TEWL (h). IFE, interfollicular epidermis; Inf, infundibulum; SG, 229 
sebaceous gland; JZ junctional zone; Bu, bulge; HG, hair germ. Scale bars 50 μm (d, f); 100 µm 230 
(e). Dashed lines: epidermal-dermal boundary. ***p=0.0010 (g, p63); ***p=0.0005; *p=0.0330, 231 
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**p = 0.0071 (g, Ki67); **p=0.0083 (g, EdU). **p=0.0044, 0.0011 (h). *p=0.0167 (i), n=16 232 
sections and wholemounts analyzed over 4 mice per group. n.s., non significant.  233 
 234 
Fig. 3. Accumulation of short ribosome footprints and global translational changes in Pelo 235 
knockout epidermis (a) Metagene analysis of full length and short RPFs near the start (left) and 236 
stop (right) codons. (b) RPF read length distributions. (c) Empiric cumulative distribution plot of 237 
global enrichment of short 20-21nt relative to expected 28-34nt reads. (d) Designations of -15 238 
peaks indicate positions of 5´ end of RPF; corresponding P site occupancy shown. (e) Relative 239 
enrichment of short RPFs (y-axis) and change in RNA transcript levels (x-axis). (f) Replicate 240 
analysis of translational efficiency (TE). (g) MA plot showing observed and expected variance in 241 
TE measurements; p-adjusted <0.01, blue transcripts. (h) Canonical pathways linked to 242 
translation regulation in PeloepiKO. (i) Epidermal polysome profiling. (j) qRT-PCR shows 243 
significant increase in heavy polysome bound Krt86 mRNA; p=0.019.  244 
 245 
Fig. 4. Inhibition of mTOR pathway attenuates Pelo phenotype progression (a-d, r, t, v) 246 
Immunolabelling for markers indicated. (s, u) Quantitation: **p=0.0064 (s); ***p=0.0006 (u). 247 
(b-l) OP-Puro injected newborn (b-j) and adult (k, l) mice. (e-k) Representative flow histograms 248 
and (i, j, l) quantitation; n=3 mice per group. *p=0.0406 (i), 0.0357 (j), 0.0198 (l). (m-v) 4-OHT 249 
and rapamycin (Rapa) treatment. (o) TEWL; *p=0.0145. (p, q) H&E stained dorsal skin. 250 
*p=0.0286. Scale bars 50 μm (a); 100 μm (b-d; p, r, s, v), n=12 sections and wholemounts 251 
analyzed over 4 mice per group per group.  252 
 253 
 254 
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Methods 339 
 340 
Mouse strains 341 
All mouse experiments were performed under a UK Government Home Office project license 342 
and subject to local institutional ethical approval. The generation of conditional Pelofl/fl 343 
(Pelotm1Imad) mice was described elsewhere32. To derive constitutive Pelo epidermal knockout 344 
mice (PeloepiKO), Pelofl/fl mice were crossed with Krt14Cre mice (Jax strain, stock number 345 
004782). To achieve temporally controlled Pelo knockout and genetic labeling of cells lacking 346 
Pelo, Pelofl/fl mice were crossed with Krt14CreERT (Jax strain, stock number 005107), Lrig1EGFP-347 
IRES-CreERT2 mice31, Lgr5EGFP-IRES-CreERT2 mice33, Lgr6EGFP-IRES-CreERT2 mice34 and Rosa26LoxP-Stop-348 
LoxP-tdTomato mice35. To activate Cre recombinase, 4-Hydroxytamoxifen (4-OHT, Sigma-Aldrich) 349 
was dissolved in acetone and applied topically (3 mg/100 μl) every day for five days and once a 350 
week for three weeks. For proliferation assays, 5-ethynyl-2′-deoxyuridine (EdU) (Invitrogen, 20 351 
mg kg-1   body mass; in PBS) was injected intraperitonially and the tissue was harvested 1 hr 352 
later. To derive constitutive Pelo dermal knockout mice (PeloderKO), Pelofl/fl mice was crossed 353 
with Dermo1Cre (B6.129X1-Twist2tm1.1(cre)Dor/J)36,37. Mouse lines used in this study with the 354 
location of expression of markers in the skin are illustrated in the Extended Data Fig. 10k.  355 
Hbs1l-/-  (Hbs1ltm1a(KOMP)Wtsi) mice were produced at the Wellcome Trust Sanger Institute Mouse 356 
Genetics Project as part of International Mouse Phenotype Consortium (IMPC)38.  357 
Library generation for ribosome profiling 358 
Samples of PeloepiKO epidermis for ribosome profiling and RNA-Seq were prepared by scrapping 359 
off the epidermal layer in liquid nitrogen. Frozen samples were ground using a Mixer Mill 360 
(Retch) and thawed in the presence of polysome lysis buffer. Lysates were clarified by 361 
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centrifugation at 20,000g for 10 minutes at 4˚C and the supernatant was collected. Total lysate 362 
RNA was quantified using the Quant-it RNA kit (Thermo) and 5 µg was used for preparation of 363 
ribosome profiling libraries as described previously15. Total RNA was size-selected by excising 364 
gel regions between phosphorylated 16nt and 34nt RNA oligo standards. Ribosomal RNAs were 365 
depleted using Ribo-Zero Gold (Illumina) after footprint size-selection. 100ng was used for 366 
preparation of RNA-Sequencing libraries from the same samples as profiling libraries. Analysis 367 
using a BioAnalyzer total RNA pico chip was used to confirm RNA integrity (RIN >9) for RNA 368 
sequencing samples. The datasets are deposited in GEO under accession number GSE94385. 369 
 370 
Sequencing and data analysis 371 
Ribosome profiling and RNA-Seq libraries were sequenced using a HiSeq2500 (Illumina). ~110 372 
million total raw reads were generated from 4 ribosome profiling samples with between 11 and 373 
30 million reads mapping to the genome per sample. For ribosome profiling analysis, only 374 
singly-mapped reads (NH:i:1) with no mismatches (NM:I:0) were used. Translational efficiency 375 
(TE) was calculated as number of CDS RPFs / RPKM. Relative 3´UTR ribosome occupancy was 376 
calculated as 3´UTR footprint density / CDS footprint density. For differential gene expression 377 
analysis, we uploaded the list of differentially expressed genes into Ingenuity IPA and ran a core 378 
analysis. This identified the top molecules, pathways and master regulators that are different 379 
between control and PeloepiKO samples. 380 
 381 
Polysome analysis 382 
Epidermal layers from WT and Pelo epiKO were lyzed as described above (see Library generation 383 
for ribosome profiling). Clarified lysates were loaded on 10-50% sucrose gradients prepared in 384 
polysome gradient buffer (20mM Tris-HCl [pH8], 150mM KCl, 5mM MgCl2, 0.5mM DTT, 385 
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0.1mg/mL cycloheximide), and gradients were spun in an SW41-Ti rotor at 40,000 rpm for 3 hr 386 
at 4°C. Gradients were fractionated using a Brandel Density Gradient Fractionation System. 387 
Prior to RNA extraction, CLuc mRNA (NEB) was added in each fraction. RNA was extracted 388 
using hot acidic phenol and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad) 389 
according to manufacturer’s instructions. qPCR was carried out using iTaq Universal SYBR 390 
Green Supermix (Bio-Rad). Relative mRNA abundances in indicated fractions were normalized 391 
to CLuc mRNA to account for differences in RNA extraction efficiency among fractions, and 392 
then calculated as fold changes normalized to 80S fractions. qPCR primers:  CLuc Forward 5 ́-393 
GCTTCAACATCACCGTCATTG-3’, CLuc Reverse 5’-CACAGAGGCCAGAGATCATTC-3 ́, 394 
Krt86 Forward 5’-AACAGAATGATCCAGAGGCTG–3’, Krt86 Reverse 5’- 395 
GCTCAGATTGGGTCACGG-3’. 396 
 397 
RNA-seq library preparation and analysis 398 
Primary epidermal cell suspension was prepared as previously described39. Briefly, cells were 399 
harvested from 3 months old 4-OHT treated Pelofl/+; Lrig1EGFP-CreERT2, Pelofl/+; Lgr5EGFP-CreERT2, 400 
Pelofl/+; Lgr6EGFP-CreERT2 control mice and Pelofl/fl; Lrig1EGFP-CreERT2, Pelofl/fl; Lgr5EGFP-CreERT2, 401 
Pelofl/fl; Lgr6EGFP-CreERT2 Pelo mut mice. Total epidermal population was FACS sorted for GFP+ 402 
cells on a BD FACSAriaII cell Sorter and 1000 GFP-high cells collected from each population 403 
for RNA-seq. Library construction and the strategy for RNA-seq was performed using Smart-404 
seq2 method as reported previously40. Fastq files of paired-end reads were uploaded to Galaxy 405 
platform41 and aligned using STAR aligner42 to Mus musculus reference genome 406 
(GRCm38/Mm10). BAM files were processed in R using “rnaseqGene” workflow43. The data 407 
were analysed using the edgeR package. Processed data were mined using IPA Ingenuity 408 
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Pathway Analysis (Qiagen). The datasets are deposited in GEO under accession number 409 
GSE106246. 410 
 411 
Flow cytometry for measurement of cell size, cycle and protein synthesis in vivo 412 
To analyse cell size by flow cytometry, epidermal cells were isolated as previously described39. 413 
Briefly, epidermis was enzymatically separated from dermis with thermolysin (Sigma, 0.25 414 
mg/mL in PBS) overnight at 4°C. Epidermal sheets were processed into single cell suspensions 415 
by incubation in DMEM (Gibco) containing DNAse (Sigma, 250 µg/mL) for 20 min at 37°C 416 
with shaking. Single cells were labelled according to standard procedures with anti- Integrin α6-417 
Alexa Fluor 647 or FITC (AbSource, 1:20) antibody. To assess the percentage of proliferating 418 
epidermal cells, mice were injected with 500µg 5-ethynyl-2’-deoxyuridine (EdU; 2.5mg/mL in 419 
PBS) intraperitoneally and back skin was harvested 2 hr later. Cells were isolated as described 420 
above and single cell suspensions were stained with the Click-iT EdU Alexa Fluor 488 Flow 421 
Cytometry Kit (Invitrogen) according to the manufacturer’s suggestions. Cell cycle analysis was 422 
performed on a BD LSR Fortessa cell analyser. Proliferating cells that had incorporated EdU 423 
were detected in the FITC/Alexa Fluor 488 channel. 424 
 425 
To measure protein synthesis in vivo, mice received an intraperitoneal injection of O-propargyl-426 
puromycin (OP-P) (Medchem Source or Thermo Fisher (C10459); 50 mg kg-1 body mass; pH 427 
6.4–6.6 in PBS). One hour later mice were euthanized and back and tail skin samples were 428 
collected. Epidermal dissociation was performed as described above. The staining for detection 429 
of protein synthesis was performed according to the manufacturer instructions (Click-iT Plus 430 
OPP Protein Synthesis Assay Kit; Thermofisher Scientific). Samples from PBS-injected mice 431 
were also stained for detection of protein synthesis and the fluorescence signal was used to 432 
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determine background labelling. Rates of protein synthesis were calculated as described 433 
previously3. Briefly, OP-P signals were normalized to whole epidermis after subtracting 434 
autofluorescence background. ‘Mean OP-Puro fluorescence’ reflected fluorescence values for 435 
each cell population normalized to whole epidermis. Labelled cells were analysed on a BD 436 
LSRFortessa cell analyser. All data were analysed using FlowJo software.  437 
 438 
Histology, epidermal wholemounts and imaging 439 
For paraffin sections, skin samples were fixed with 10% neutral buffered formalin overnight 440 
before paraffin embedding. The tissues were sectioned and stained with haematoxylin and eosin 441 
(H&E) and Herovici’s stain by conventional methods. For frozen sections, skin samples were 442 
embedded on OCT (optimal cutting temperature compound; VWR), sectioned and fixed in 4% 443 
PFA for 10 min before staining. Slides were mounted using ProLong Gold anti-fade reagent 444 
containing DAPI (Life Technologies) as a nuclear counterstain. Images were acquired using a 445 
Hamamatsu slide scanner and analysed using NanoZoomer software (Hamamatsu). 446 
The epidermal wholemount labelling procedure was performed as described previously44,45. In 447 
brief, mouse tail was slit on the ventral side lengthways. Pieces (0.5x0.5 cm2) of skin were 448 
incubated in 5 mM EDTA in PBS at 37 °C for 4 h. Epidermis was gently peeled from dermis as 449 
an intact sheet in a proximal to distal direction, corresponding to the orientation of the hairs, and 450 
then the epidermis was fixed in 4% paraformaldehyde (PFA; Sigma) for 1 h at room temperature. 451 
Fixed epidermal sheets were washed in PBS and stored in PBS containing 0.2% sodium azide at 452 
4° C.  453 
Confocal image acquisition of stained wholemounts and skin sections were performed using a 454 
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Nikon A1 confocal microscope. Images were analysed using NIS Elements (Nikon Instruments 455 
Inc.). Photoshop CS5 (Adobe image suite) was used to optimize the images globally for 456 
brightness, contrast and colour balance.  457 
Rapamycin treatment 458 
Rapamycin (LC Laboratories, R5000) was dissolved in acetone. Rapamycin treatment groups 459 
received topical applications of 500 μl 0.2% Rapamycin on dorsal and tail skin. Vehicle 460 
treatment group mice received an equal volume of acetone without rapamycin. Dorsal skin was 461 
shaved before the day of treatment. 462 
 463 
Wound and TEWL assays  464 
Full-thickness wounds were made on the lower dorsal skin (5mm) or tail (2mm) using punch 465 
biopsy (Stiefel) under analgesia and general anaesthesia. The hair on the back was shaved prior 466 
to wounding. Wound closure was measured using a Vernier scale. Epidermal barrier function 467 
was assessed by testing basal transepidermal water loss (TEWL) on the dorsal skin of mice using 468 
a TEWAmeter (Courage and Khazaka, TM210). Measurements were collected for 15–20 469 
seconds when TEWL readings had stabilized, at approximately 30 seconds after the probe collar 470 
was placed on the dorsal skin. 471 
 472 
Antibodies 473 
Primary antibodies for wholemount and tissue sections were: chicken anti-Krt14 (Covance, 474 
SIG2376, 1:500) or directly conjugated (AlexaFluor 555) Krt14 (LL002, in house, 1:200); 475 
directly conjugated (AlexaFluor 488) Krt15 (LHK-15, in-house, 1:50); human anti-p63 (SCBT, 476 
sc367333, 1:100); rabbit anti-filaggrin (Covance, PRB-417P, 1:100); mouse anti-FASN (SCBT, 477 
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sc48357, 1:100); rabbit anti-Ki67 (Novocastra, NCL-Ki67p, 1:500); rabbit anti-Ki67 (abcam, 478 
ab16667, 1:500); rabbit anti- Phospho-S6 Ribosomal Protein (Ser235/236)  (pS6K, Cell 479 
signaling, 2211, 1:200); rabbit anti-P-Cadherin (Cell signaling, 2130, 1:200); rabbit anti-480 
Vimentin (Cell signaling, 5741s, 1:500); rabbit anti-K10 (Covance, PRB-159P, 1:500); FITC 481 
conjugated rat anti-CD49f (Integrin 6, Biolegend, 313606, 1:100); goat anti-Lrig1 (R&D 482 
Systems, FAB3688G, 1:200); rabbit anti-Scd1 (Cell signaling, 2794s, 1:500); mouse anti-483 
involucrin (SY5, in-house, 1:500); mouse anti-Pankeratin (abcam, ab8068, 1:200); rat anti-CD34 484 
(RAM34, Thermo Fisher, 14-0341-82, 1:200); Rabbit anti-Phospho-4EBP1 (Thr37/46) (Cell 485 
Signalling, 236B4, 1:500) AlexaFluor (Life Technologies) dye-conjugated secondary antibodies 486 
were used at 1:250 dilutions.  487 
 488 
In vitro knockdown, clonogenicity and skin reconstitution assay 489 
Primary human keratinocytes (strain km) were isolated from neonatal foreskin and cultured on 490 
mitotically inactivated 3T3-J2 feeder cells in complete FAD medium, containing 1 part Ham's 491 
F12 medium and three parts Dulbecco's modified Eagle’s medium (DMEM), 10-4 M adenine, 492 
10% (v/v) FBS, 0.5 μg ml-1 hydrocortisone, 5 μg ml-1 insulin, 10-1 M cholera toxin and 10 ng 493 
ml-1 EGF, as described previously46,47. siRNA mediated gene silencing was performed as 494 
described previously48. Briefly, keratinocytes were transferred to feeder free conditions in 495 
keratinocyte serum-free medium (KSFM) containing 30 μg ml−1 BPE (bovine pituitary extract) 496 
and 0.2 ng ml−1 EGF (Gibco) for 2–3 days. Cells were trypsinized at ~70% confluence and 497 
resuspended in cell line buffer SF (Lonza). For each 20μl transfection (program FF-113), 2×105 498 
cells were mixed with 1–2μM siRNA duplexes (Silencer select siRNA for PELO ID131910, 499 
ID131911, ID131912, as well as negative control, Ambion). Transfected cells were incubated at 500 
  21
room temperature for 5–10 min and subsequently resuspended in pre-warmed KSFM. siRNA 501 
nucleofections were performed with the Amaxa 16-well shuttle system (Lonza). Alternatively, 502 
keratinocytes cells were transfected by using INTERFERin (Polyplus transfections): 36pmol 503 
siRNA, 4ul INTERFERin reagent, and 200ul KSFM were mixed in the collagen coated (20ug/ml 504 
in PBS, 1h, 37°) 12-well plate and incubated 20min at room temperature. After the incubation, 505 
75, 000 keratinocytes were seeded to the well (final concentration of siRNA 30nM). Medium 506 
was changed after 4 hrs and cells were harvested after 48 hrs.  507 
 508 
For clonogenicity assays, nucleofected keratinocytes were seeded at low density (100-250 cells 509 
per well) on a prepared feeder layer in 6-well plates containing FAD medium. Keratinocytes 510 
were maintained in culture for 12 days and then feeders were removed by Versene treatment 511 
combined with tapping the culture flask. Once all the feeder cells were washed away, the 512 
remaining keratinocytes colonies were fixed with 4% PFA at room temperature for 10 min. 513 
Colonies were then stained with 1% Rhodanile Blue (1:1 mixture of Rhodamine B and Nile Blue 514 
A (Acros Organics) solution for 15min and washed with distilled water prior to examination. 515 
Stained dishes containing keratinocyte colonies were imaged using a Molecular Imager Gel Doc 516 
XR+ imaging system (Bio-Rad). Colonies were measured using ImageJ and clonogenicity was 517 
calculated as the percentage of plated cells that formed colonies. 518 
 519 
For the skin reconstitution assay, pre-confluent keratinocyte cultures (KM passage 3) were 520 
disaggregated and transfected either with PELO siRNAs or scrambled control siRNAs. 24 hours 521 
post-transfection, keratinocytes were collected and reseeded on irradiated de-epidermised human 522 
dermis in 6-well Transwell plates with feeders and cultured at the air–liquid interface for three 523 
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weeks49. Organotypic cultures were fixed in 10% neutral buffered formalin (overnight), paraffin 524 
embedded and sectioned for H&E and immunofluorescence analysis.  525 
 526 
Picrosirius birefringence and dermal thickness and cell density  527 
12µm paraffin sections were stained with picrosirius red using a standard method50. Briefly, the 528 
sections were de-paraffinized, washed twice with water and stained 1 hr in picrosirius red 529 
solution (0.1% Sirius red F3B in saturated aqueous solution of picric acid). After the staining, 530 
sections were washed twice with acidified water (0.5 % acetic acid), dehydrated, cleared with 531 
xylene, and mounted with DPX mounting medium. The images were acquired using Zeiss 532 
Axiophot microscope and AxioCam HRc camera under plane-polarized light. The quantification 533 
of total collagen fibers was performed by Fiji (ImageJ) software. The collagen pixels were 534 
selected by Color Treshold tool (Hue 0-100, Saturation 0-255 and Brightness 230-255).  535 
Thickness of dermis was quantified by NanoZoomer Digital Pathology software (Hamamatsu). 536 
The number of cells was determined with ImageJ by counting the nucleus in DAPI stained tissue 537 
sections.  538 
 539 
Statistics 540 
Statistical significance in all experiments was calculated by Student’s t test. Data are represented 541 
as mean ±SEM (error bars). GraphPad Prism was used for calculation and illustration of graphs. 542 
 543 
Data Availability 544 
All experimental data generated during/and or analysed this study are included in this published 545 
article (and its supplementary information files). In addition, ribosome profiling data (accession 546 
number GSE94385) and RNAseq data (accession number GSE106246) are available in GEO. 547 
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Extended Data Figure 1. Pelo is expressed in all skin cell subpopulations and Knockout of 600 
Hbs1l leads to mild dermal phenotype (a, b) Pelo and Hbs1l are ubiquitously expressed in all 601 
cell populations of embryonic and neonatal skin. mRNA expression data obtained from hair and 602 
skin gene expression library (Hair-GEL; www.hair-gel.net). (c) Schematic of Hbs1l knockout-603 
first allele. (d) Immunolabelling of tail epidermal wholemounts with antibodies to Krt14, Krt15, 604 
Lrig1 and FASN. (e) Tail skin sections immunolabelled for Ki67, showing no significant change 605 
in the distribution of Ki67+ cells in Hbs1l-/- epidermis. (f) H&E staining of adult control and 606 
Hbs1l-/- tail skin.  (g) Herovici’s polychrome staining to visualize immature (blue) and mature 607 
(pink) dermal collagen. (h) Picrosirius staining of tail skin showing the birefringence of collagen 608 
fibers against a black background. (i) Immunostaining of tail skin sections with pan-keratin 609 
(PanKrt) and vimentin (Vim) antibodies. (j-m) Quantification of dermal thickness (j), dermal cell 610 
density (k), dermal cellularity (l) and total collagen deposition (m). Dashed lines mark 611 
epidermal-dermal boundary. Scale bars 100 μm. *p = 0.0286 in (j, m). n=12 sections analyzed 612 
over 4 mice per group. FKPM - Fragments per Kilobase of transcript Per Million mapped reads.  613 
 614 
Extended Data Figure 2. Delayed wound closure in Pelo null epidermis (a) Histology of skin 615 
10 days post wound (dpw) shows delayed wound closure in PeloepiKO. (b, c) EdU staining of 10 616 
dpw skin shows reduced proliferation in wound bed. Itgα6 staining demarcates dermal-617 
epidermal boundary, Box indicates the wound bed (d) Histology of 5 dpw wound shows altered 618 
epidermal architecture. (e, f) EdU labelling of 5 dpw skin shows reduced proliferation at wound 619 
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edge. (g, h) Immunostaining of Krt14 in 10 and 5 dpw skin shows abnormal differentiation in 620 
PeloepiKO (arrows). (i) TdTomato genetic labeling shows the contribution of Lrig1, Lgr5 and 621 
Lgr6 progeny in tail wound healing. Note that altered migration of Lrig1 cells in Pelofl/fl; 622 
Lrig1CreERT; tdTom when compared to Lgr5 and Lgr6 on Pelo deletion. *p = 0.0123 in (c), *p = 623 
0.0330 in (e), n=9 sections analyzed over 3 mice per group. Scale bars, 100 μm.  624 
 625 
Extended Data Figure 3. Pelo deletion leads to progressive hair follicle and sebaceous gland 626 
abnormalities (a, b, c) Confocal images of tail epidermal wholemounts immunostained for 627 
Krt14, hair follicle bulge markers CD34 and Krt15, sebocyte maturation marker Fatty acid 628 
synthase (FASN) and junctional zone stem cell marker Lrig1 show progressive changes in hair 629 
follicle and sebaceous gland structure from P16 to P120 in PeloepiKO mice. Note that the FASN 630 
staining in P84 and P120 PeloepiKO epidermis is non-specific due to highly keratinized hair 631 
follicles. Asterisks in (b) indicate non-specific staining of sebaceous glands.  Scale bars, 100 μm. 632 
 633 
Extended Data Figure 4. Postnatal epidermal Pelo deletion impairs barrier function and 634 
wound healing (a, b) Breeding scheme and topical Tamoxifen (4-OHT) treatment regime. (c) 635 
Representative Pelofl/fl; Krt14CreERT mouse showing skin lesions (dashed area) in 4-OHT-treated 636 
dorsal skin. (d) TEWL is increased in 4-OHT-treated skin of Pelofl/fl; Krt14CreERTmice. (e) Rate 637 
of wound closure. (f) Tail epidermal wholemounts immunostained with Krt14 and Krt15 638 
antibodies showing altered sebaceous gland architecture (arrows) in 4-OHT-treated Pelofl/fl; 639 
Krt14CreERT mice. (g) Tail epidermal wholemounts from TdTomato (red) genetically labelled 640 
Pelofl/fl; Krt14CreERT mice show keratinized cysts in hair follicles (arrows). (h) Cumulative mean 641 
values of gene expression obtained from ribosome profiling show down-regulation of markers of 642 
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sebaceous gland differentiation and increase in Myc. (i) Tail epidermal wholemounts showing 643 
altered expression of FASN, Scd1 and Lrig1 (arrows) in sebaceous glands of 4-OHT-treated 644 
Pelofl/fl; Krt14CreERT mice (middle and right panels). Dashed lines indicate pilosebaceous units. 645 
Scale bars, 100 μm. **p = 0.0072, *p = 0.0650, n. s., non significant. n = 3 in treated and 646 
untreated control groups. 647 
 648 
Extended Data Figure 5. Knockdown of PELO in human keratinocytes phenocopies mouse 649 
epidermal phenotype and proliferation difference in mice lacking Pelo in Lrig1, Lgr5 and 650 
Lgr6 stem cells. (a-d) PELO knockdown validation. (a) qRT-PCR for individual siRNAs 651 
transfected in human primary keratinocytes. (b) Clonal growth. (c, d) colony number and average 652 
size of individual colonies. (e-g) Clonal growth of keratinocytes, comparing pooled PELO 653 
siRNA knockdown (PELOsiRNA) and scrambled (Scr) control. (h-l) Effect of PELO knockdown 654 
in human epidermal reconstitution assay on decellularised dermis. (h, i) Epidermal thickness of 655 
DED cultures is significantly increased on PELO knockdown. (j-l) Immunolabelling for Krt14 656 
(K14), Ki67, p63 and differentiation markers Krt10 (K10) and involucrin (IVL) shows increased 657 
number of differentiated cell layers (j) and increased number of cells expressing Ki67 and p63 658 
(k, l) in PELOsiRNA reconstituted epidermis. Dashed lines indicated dermal-epidermal boundary. 659 
Assessing proliferation by Ki67 and p63 in the dorsal skin IFE sections of mice lacking Pelo in 660 
Lrig1, Lgr5 and Lgr6 stem cells.  Scale bars, 100 μm. ***p = 0.0009 (a, for siRNA#10), ***p = 661 
0.0004 (a, for siRNA#11), **p = 0031 (a, for siRNA#12); *p =  0.0286 (c); *p = 0.0286 (d); **p 662 
= 0.0022 (f); **p = 0.0087 (g); ****p = < 0.0001 (i);  *p = 0.0229 for Ki67 and *p = 0.0107 for 663 
p63 (l). n = 2 independent transfections; n = 3 dishes (a - g) and n = 2 sections of reconstituted 664 
epidermis (h, l).  665 
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Extended Data Figure 6. Lrig1+ stem cells account for Pelo mutant epidermal phenotype 666 
(a) Tail epidermal wholemounts labeled with Krt14 and Ki67 antibodies, showing increased 667 
proliferation and alterations to the junctional zone (asterisks) and sebaceous glands (arrow) in 668 
Pelofl/fl; Lrig1CreERT2 mice. (b) Cross section of dorsal skin stained for EdU shows increased 669 
proliferation and alterations in HF infundibulum structure (arrow) in Pelofl/fl; Lrig1CreERT2 mice. 670 
(c-e) Confocal images of tail epidermal wholemounts (c, e) and dorsal skin sections (d) of 671 
tdTomato labelled Pelofl/fl; Lrig1CreERT2, Pelofl/fl; Lgr5CreERT2 and Pelofl/fl; Lgr6CreERT2 mice. (c, d) 672 
Expansion of tdTomato-labelled Lrig1 (arrows) but not Lgr5 or Lgr6 progeny upon Pelo 673 
deletion. (e, f) Increase in proliferation (Ki67 labelling) of Lrig1 (arrows) but not Lgr5 and Lgr6 674 
populations. Scale bars, 100 μm. *p = 0.0047 (f). n=9 wholemounts analyzed over 3 mice per 675 
group. All mice were in telogen of the hair cycle (2-3 months old) when treated with 4-OHT. 676 
Treatment regime and harvest of tissue were as indicated in Fig. 2c. Dashed lines mark 677 
epidermal-dermal boundary. 678 
 679 
Extended Data Figure 7. Pelo knockout epidermal cells do not accumulate 3´UTR 680 
footprints (a) Empiric cumulative distribution plots of relative 3´UTR ribosome occupancy for 681 
all transcripts or (b) those with at least 1 read mapped to the 3´UTR. (c-e) Gene Ontology of 682 
genes differentially expressed in Pelo-null epidermis. Functional, component and process 683 
categories of genes enriched in PeloepiKO.  684 
 685 
Extended Data Figure 8. Computational analysis of differentially regulated pathways 686 
between control and PeloepiKO and comparison of molecular signatures in PeloepiKO and 687 
Gtpbp2-deficient brain (a) Number of genes that were differentially expressed in PeloepiKO and 688 
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control epidermis and their associated functions. (b, c) Ingenuity Pathway Analysis showing 689 
changes in mTOR pathway genes in PeloepiKO vs control epidermis (b) and their predicted 690 
molecular activities (c). (d) Venn diagram shows common differentially expressed genes in our 691 
study and that of Ishimura et al (2014) when comparing Ctrl and mutants. The 314 overlapping 692 
genes are enriched in top canonical pathways that are highly related to translation.  693 
 694 
Extended Data Figure 9. Pelo epidermal deletion results in increased protein synthesis and 695 
basal stem cell size and Rapamycin treatment reduces proliferation of Pelo-null epidermis 696 
(a) Gating strategy for measurement of OP-Puromycin incorporation in cell populations (b, c) 697 
Confocal images of tail and ear epidermal wholemounts immunolabelled for Krt14 and P-698 
cadherin (P-Cad), showing IFE basal cells. (d, e) Representative flow cytometric dot plot 699 
showing increased cell size (FSC-A) of Itgα6high cells and altered S and G2/M cell cycle phases 700 
in PeloepiKO epidermis. (f, g) Breeding scheme and rapamycin treatment regime. (h) 701 
Immunolabelling of tail epidermal wholemounts with Krt14 and Ki67 antibodies shows reduced 702 
proliferation in rapamycin-treated mice compared to vehicle-treated group. Note that there was 703 
no significant change in epidermal proliferation of control mice treated with rapamycin when 704 
compared to vehicle treated mice. (i, j) Cross sections of IFE from PeloepiKO and control back 705 
skin immunolabelled with Krt14 and Ki67 antibodies, showing significant reduction in Ki67+ 706 
and suprabasal Krt14+ cells in rapamycin-treated compared to vehicle-treated mice. (k) Cross 707 
sections of IFE from control and PeloepiKO back skin immunolabelled with Krt14 and pS6K 708 
antibodies showing marked increase in pS6K labeling indicating mTOR hyperactivation in 709 
vehicle-treated PeloepiKO skin. (l) Cross sections of IFE of control and Pelofl/fl; Krt14CreERT mice 710 
(with simultaneous 4-OHT and Rapamycin treatment) immunolabelled for Krt14 and EdU 711 
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showing significant reduction in EdU+ and suprabasal Krt14+ cells in rapamycin-treated 712 
compared to vehicle-treated mice. (m) Cross sections of IFE of control and Pelofl/fl; Krt14CreERT 713 
mice (with simultaneous 4-OHT and Rapamycin treatment) immunolabelled for Krt14 and 714 
p4EBP antibodies. Note reduced pS6K labeling (k) and p4EBP1 (m) in rapamycin-treated 715 
epidermis. Gray scale images for pS6K are shown below merged images. Scale bars, 100 μm. *p 716 
= 0.0132 in (j), n. s., non significant. n=9 sections analyzed over 3 mice per group. Dashed lines 717 
mark epidermal-dermal boundary. 718 
 719 
Extended Data Figure 10. RNA-sequencing of Lrig1+, Lgr5+ and Lgr6+ cells reveals Lgr5 720 
as a transcriptionally unique subpopulation and subtle changes in transcription in all 721 
subpopulations when Pelo is deleted. (a) Schematic illustration of the EGFPhigh sorting and 722 
RNA-seq strategy for control and Pelo-deleted subpopulations using Pelofl/fl; Lrig1EGFP-CreERT2, 723 
Pelofl/fl; Lgr5EGFP-CreERT2 and Pelofl/fl; Lgr6EGFP-CreERT2 mice. (b) Principal component analysis of 724 
RNA-seq data shows that the Lgr5 subpopulation is remarkably different from the other two. 725 
Note that there is no major change in the clusters when Pelo is deleted in any of the 726 
subpopulations. (c) Hierarchical clustering of the subpopulations corroborates minimal 727 
transcriptional changes between control and Mut mice, revealing two major clusters, one for 728 
Lgr5 and another for Lrig1 and Lgr6. (d) Venn diagram illustrating the differentially expressed 729 
genes in common between the 3 subpopulations when comparing control and Mut. (e) Top 730 
differentially regulated transcription factors between Lrig1 and Lgr5 (f), Lgr5 and Lgr6 (g) and 731 
Lrig1 and Lgr6 control subpopulations. (h-j) Top differentially regulated canonical pathways 732 
between Lrig1 and Lgr5 (h), Lgr5 and Lgr6 (i) and Lrig1 and Lgr6 control subpopulations (j). (k) 733 
Schematic of epidermis showing location of marker expression and the various transgenic mice 734 
used in this study.  735 
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